US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Yesterday's Top Gainers

805.83

+2.920.36%

Number of Gainers:29

Number of Losers:19

Number of Flat:5

PE:- -

High:809.29

Open:802.90

Low:800.35

Close:802.92

Volume:16.87M

Turnover:228.13M

Market Cap:135.77B

Float Cap:82.27B

Loading ...

Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access

MT Newswires Live

GOLDWAY EDU Completes Share Placement, Raising Approximately HK$4.4 Million Net

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Humacyte Says Phase 3 V012 Trial Shows ATEV Extends Catheter-Free Dialysis Time in Women

Humacyte - Seeks to Add Dialysis Access as Second Approved Indication for Atev

THOMSON REUTERS

Humacyte - Supplemental Bla to be Supported by Three Phase 3 Studies of Atev

THOMSON REUTERS

Humacyte - to File Supplemental Bla with FDA for Atev in Dialysis Access in November 2026

THOMSON REUTERS

Humacyte Confirms Plans for Atev Supplemental Bla Filing for Dialysis Access Following FDA Discussions

THOMSON REUTERS

Napco Security Soars After Robust Q4 Results

Regenxbio Shares Down 25% Premarket After FDA Places Clinical Hold on Co's Gene Therapy for Hunter Syndrome

THOMSON REUTERS

Regenxbio reports FDA placed clinical hold on RGX-121

NAPCO Security Technologies Raises Quarterly Dividend by 13%

NAPCO Q4 Revenue Beats on Recurring Service Rev Growth

3 Stocks Estimated To Be Trading Below Intrinsic Value By 37.9% To 46.8%

Simply Wall St.

3 Growth Companies With High Insider Ownership And Up To 89% Earnings Growth

Simply Wall St.

FDA Places Clinical Hold on Regenxbio RGX-121 Gene Therapy for Hunter Syndrome After Spine MRI Findings

Regenxbio - Co and Ns Pharma Evaluating Additional Data for Rgx-121

THOMSON REUTERS

Regenxbio - FDA Places Clinical Hold on Rgx-121 After Spine Mri Findings

THOMSON REUTERS

Regenxbio - Does not Expect to Resubmit Rgx-121 Bla in Near Term

THOMSON REUTERS

Napco Security Technologies Shares up 10.3% Premarket After Q4 Revenue Beat

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK4563/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4563","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4563\",,,,,undefined,":{"symbol":"BK4563","market":"US","secType":"PLATE","nameCN":"Yesterday's Top Gainers","latestPrice":805.83344,"timestamp":1788361252988,"preClose":802.9162,"halted":0,"volume":16870075,"delay":0,"changeRate":0.003633,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":2.917236,"latestTime":"09-02 11:00:53 EDT","open":802.8956,"high":809.2909,"low":800.35077,"amount":228131571.123131,"amplitude":0.011135,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":1.896387,"peRate":33.446648,"turnoverRate":0.003028,"increases":29,"decrements":19,"flats":3,"marketCap":135771889309,"floatMarketCap":82274741300.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4563\",,,,,undefined,":{"symbol":"BK4563","high":809.2909,"amplitude":0.011135,"preClose":802.9162,"low":800.35077,"pbRate":"1.896387","latestPrice":805.83234,"volume":16865199,"delay":0,"open":802.8956,"prevYearClose":890.65686,"prevWeekClose":811.513,"prevMonthClose":801.6147,"prevQuarterClose":730.3676,"fiveDayClose":817.8341,"twentyDayClose":798.2692,"sixtyDayClose":766.0779,"secType":"PLATE","market":"US","turnoverRate":0.003028,"peRate":33.446648,"marketCap":135771889309,"floatMarketCap":82274741300.75,"timestamp":1788361249387,"nameCN":"Yesterday's Top Gainers"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4563\",,,,undefined,":{"bkCode":"BK4563","up":29,"down":19,"flat":5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4563\",pageSize:20,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661927919","title":"Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access","url":"https://stock-news.laohu8.com/highlight/detail?id=2661927919","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661927919?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:52","pubTimestamp":1787575979,"startTime":"0","endTime":"0","summary":"Humacyte  said Monday it plans to file in November a supplemental biologics license application with the US Food and Drug Administration to seek approval for the use of its acellular tissue engineered vessel in dialysis access.The company said it will support the filing with data from three phase 3 trials, including a study where female dialysis patients averaged three additional months without a catheter compared with standard of care.The product received regulatory approval in December 2024 for vascular trauma, Humacyte said.Shares of the company were up 6.4% in Monday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","HUMA","BK4563","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198070319","title":"GOLDWAY EDU Completes Share Placement, Raising Approximately HK$4.4 Million Net","url":"https://stock-news.laohu8.com/highlight/detail?id=1198070319","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198070319?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:44","pubTimestamp":1787575457,"startTime":"0","endTime":"0","summary":"GOLDWAY EDU (08160) has announced that all conditions precedent under its placement agreement have been satisfied, with the placement officially completed on August 24, 2026.Under the terms of the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1228","BK4535","BK4505","LU0359202008.SGD","LU0823426480.USD","LU0455707207.USD","EDU","BK4503","BK4585","BK4506","BK4510","08160","LU2242644610.SGD","LU0502904849.HKD","BK4588","BK4204","LU0572944931.SGD","LU0048580855.USD","LU1023057109.AUD","LU0370786039.SGD","LU0359201612.USD","BK4563","LU0823426308.USD","LU0327786744.USD","BK4509","BK4531","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279989","title":"Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279989","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279989?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:39","pubTimestamp":1787575140,"startTime":"0","endTime":"0","summary":"Regenxbio shares plunged Monday following a regulatory hold on its investigational gene therapy-the biotechnology company's second program paused by regulators in recent months.An expanded MRI program","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","BK4505","SRPU","LU0109394709.USD","BK4139","IE0002141913.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4585","LU0889565916.HKD","IE0009355771.USD","BK4588","BK4563","SRPT","IE00BJT1NW94.SGD","RGNX","LU0320765992.SGD","BK4007","EYPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276879","title":"Humacyte Says Phase 3 V012 Trial Shows ATEV Extends Catheter-Free Dialysis Time in Women","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276879","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276879?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572824,"startTime":"0","endTime":"0","summary":"Humacyte says Phase 3 V012 trial shows ATEV extends catheter-free dialysis time in womenHumacyte set a November 2026 supplemental BLA filing to expand its ATEV into dialysis access, following FDA disc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL1qK8gS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","BK4585","HUMA","IE00BQXX3D17.EUR","BCDF","BK4588","SG9999014013.SGD","BK4139","IE00BQXX3C00.GBP","BK4112","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","NDAQ","BK4563","IE00BQXX3F31.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661768672","title":"Humacyte - Seeks to Add Dialysis Access as Second Approved Indication for Atev","url":"https://stock-news.laohu8.com/highlight/detail?id=2661768672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661768672?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA90KKJQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HUMA","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276898","title":"Humacyte - Supplemental Bla to be Supported by Three Phase 3 Studies of Atev","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276898","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276898?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA90KKJQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HUMA","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276844","title":"Humacyte - to File Supplemental Bla with FDA for Atev in Dialysis Access in November 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276844?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA90KKJQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HUMA","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276826","title":"Humacyte Confirms Plans for Atev Supplemental Bla Filing for Dialysis Access Following FDA Discussions","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276826?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA90KKJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661627521","title":"Napco Security Soars After Robust Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627521","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627521?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:48","pubTimestamp":1787572086,"startTime":"0","endTime":"0","summary":"BUZZ-Napco Security soars after robust Q4 results** Shares of Electronic security devices and fire alarm systems provider Napco Security TechnologiesNSSC.Orise 19.7% to $45.6 premarket** CopostsQ4 adj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL6N44L0LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","NSSC","BK4157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275913","title":"Regenxbio Shares Down 25% Premarket After FDA Places Clinical Hold on Co's Gene Therapy for Hunter Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275913","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275913?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:42","pubTimestamp":1787571735,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL4N44L0TU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4139","RGNX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661627309","title":"Regenxbio reports FDA placed clinical hold on RGX-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627309","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627309?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:20","pubTimestamp":1787570406,"startTime":"0","endTime":"0","summary":"Regenxbio (RGNX) provided an update on its investigational gene therapy, RGX-121, for the treatment of Mucopolysaccharidosis type II, also known as...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LFSC","IBBQ","FBT","BK4505","BK4563","TBXU","GNOM","BK4139","CNCR","IBB","BK4588","SYNB","RGNX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661810275","title":"NAPCO Security Technologies Raises Quarterly Dividend by 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661810275","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661810275?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:19","pubTimestamp":1787570340,"startTime":"0","endTime":"0","summary":"NAPCO Security Technologies' board has raised the company's quarterly dividend by 13%, to 17 cents from 15 cents.The new payout, equal to 68 cents a year, represents an annual yield of about 1.78% based on Friday's closing price of $38.09, up from 1.58%.The Amityville, N.Y., maker of security products company on Monday said the increased dividend is payable Oct. 2 to shareholders of record Sept. 11.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSSC","BK4563","BK4157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273117","title":"NAPCO Q4 Revenue Beats on Recurring Service Rev Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273117","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273117?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:10","pubTimestamp":1787569826,"startTime":"0","endTime":"0","summary":"NAPCO Q4 revenue beats on recurring service rev growthOverviewU.S. security equipment maker's fiscal Q4 revenue rose 10%, beating analyst expectationsFiscal Q4 adjusted EBITDA grew 44% and beat analys","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4020","UI","BK4157","BK4563","BK4532","NSSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271416","title":"3 Stocks Estimated To Be Trading Below Intrinsic Value By 37.9% To 46.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271416?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:07","pubTimestamp":1787569677,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has experienced a slight decline of 1.2%, yet it remains up by 18% over the past year with earnings expected to grow by 17% annually. In this context, identifying stocks that are trading below their intrinsic value can be a strategic approach for investors looking to capitalize on potential long-term growth opportunities.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/1033000-choice1-main-header/1585186680256","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/1033000-choice1-main-header/1585186680256"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/energy/nyse-cvi/cvr-energy/news/3-stocks-estimated-to-be-trading-below-intrinsic-value-by-37","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/energy/nyse-cvi/cvr-energy/news/3-stocks-estimated-to-be-trading-below-intrinsic-value-by-37","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4106","BK4563","BK4585","BK4138","BK4094","BK4588","DLO","VSXY","CVI","BK4539","BK4227"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661827148","title":"3 Growth Companies With High Insider Ownership And Up To 89% Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661827148","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661827148?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:05","pubTimestamp":1787569543,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has experienced a 1.2% decline, yet it has risen by 18% over the past year, with earnings forecasted to grow by 17% annually. In this environment, identifying growth companies with high insider ownership can be particularly appealing as it often indicates strong confidence from those closest to the business in its potential for future success.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nasdaq-tmc/tmc-the-metals/news/3-growth-companies-with-high-insider-ownership-and-up-to-89-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nasdaq-tmc/tmc-the-metals/news/3-growth-companies-with-high-insider-ownership-and-up-to-89-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4168","BK4563","LU2476274308.USD","02525","BK4528","BK4124","BK4585","TMC","LU2476274720.SGD","LU2778985437.USD","HSAI","BK4023","RNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273934","title":"FDA Places Clinical Hold on Regenxbio RGX-121 Gene Therapy for Hunter Syndrome After Spine MRI Findings","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273934","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273934?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:05","pubTimestamp":1787569525,"startTime":"0","endTime":"0","summary":"FDA places clinical hold on Regenxbio RGX-121 gene therapy for Hunter syndrome after spine MRI findingsFDA imposed a clinical hold on RGX-121 for MPS II following asymptomatic spine MRI findings in fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL1XZKy6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4139","BK4563","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661736202","title":"Regenxbio - Co and Ns Pharma Evaluating Additional Data for Rgx-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2661736202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661736202?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:05","pubTimestamp":1787569516,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L060:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RGNX","BK4505","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273625","title":"Regenxbio - FDA Places Clinical Hold on Rgx-121 After Spine Mri Findings","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273625?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:05","pubTimestamp":1787569516,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L060:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNX","BK4563","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661127367","title":"Regenxbio - Does not Expect to Resubmit Rgx-121 Bla in Near Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2661127367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661127367?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:05","pubTimestamp":1787569516,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L060:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","RGNX","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661606273","title":"Napco Security Technologies Shares up 10.3% Premarket After Q4 Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2661606273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661606273?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:04","pubTimestamp":1787569471,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL4N44L0RH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","NSSC","BK4157"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":12,"totalSize":314,"code":"91000000","status":"200"}]}}